Search

Phage biotech company Proteon Pharma (Warsaw, Poland) is hiring a business analyst.

We've seen Adaptive Phage Therapeutics (APT) in the news a lot lately—here's an interview with Greg Merril, APT's CEO, a podcast interview with a patient whose leg was saved by APT's phages, and a news article on APT's selection for Startup

Armata Pharmaceuticals and Innoviva have announced a $25 Million investment to support Armata's phage cocktail development.

BiomX announces dual listing on the Tel-Aviv stock exchange.

BiomX announces dual listing on the Tel-Aviv stock exchange.

Armata Pharmaceuticals and Innoviva have announced a $25 Million investment to support Armata's phage cocktail development.

We've seen Adaptive Phage Therapeutics (APT) in the news a lot lately—here's an interview with Greg Merril, APT's CEO, a podcast interview with a patient whose leg was saved by APT's phages, and a news article on APT's selection for Startup

The business combination transaction between AmpliPhi and C3J, two phage therapy biotech companies, is expected to close today. The new name of the combined company will be Armata Pharmaceuticals, Inc., and shares will be expected to start

The business combination transaction between AmpliPhi and C3J, two phage therapy biotech companies, is expected to close today. The new name of the combined company will be Armata Pharmaceuticals, Inc., and shares will be expected to start